ZA200506033B - Compositions and methods containing substituted quinolines and substituted diphenyl sulfones - Google Patents
Compositions and methods containing substituted quinolines and substituted diphenyl sulfonesInfo
- Publication number
- ZA200506033B ZA200506033B ZA200506033A ZA200506033A ZA200506033B ZA 200506033 B ZA200506033 B ZA 200506033B ZA 200506033 A ZA200506033 A ZA 200506033A ZA 200506033 A ZA200506033 A ZA 200506033A ZA 200506033 B ZA200506033 B ZA 200506033B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- compositions
- quinolines
- diphenyl sulfones
- methods containing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44321903P | 2003-01-27 | 2003-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200506033B true ZA200506033B (en) | 2007-01-31 |
Family
ID=32825308
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200506000A ZA200506000B (en) | 2003-01-27 | 2004-01-27 | Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin |
ZA200506033A ZA200506033B (en) | 2003-01-27 | 2004-01-27 | Compositions and methods containing substituted quinolines and substituted diphenyl sulfones |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200506000A ZA200506000B (en) | 2003-01-27 | 2004-01-27 | Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin |
Country Status (12)
Country | Link |
---|---|
US (2) | US20060035929A1 (ja) |
EP (2) | EP1594485A4 (ja) |
JP (2) | JP2006516629A (ja) |
KR (2) | KR20050119104A (ja) |
CN (2) | CN100502847C (ja) |
AT (1) | ATE465408T1 (ja) |
AU (3) | AU2004207561B2 (ja) |
CA (2) | CA2514396A1 (ja) |
DE (1) | DE602004026683D1 (ja) |
IL (1) | IL169889A (ja) |
WO (2) | WO2004066943A2 (ja) |
ZA (2) | ZA200506000B (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7344853B2 (en) | 2003-01-27 | 2008-03-18 | Baylor College Of Medicine | Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin |
US20050059656A1 (en) * | 2003-04-07 | 2005-03-17 | Cornell Research Foundation, Inc. | Compositions and methods for protecting against mitochondria component-mediated pathology |
US20070179123A1 (en) * | 2005-11-08 | 2007-08-02 | Chiang Peter K | Methods and compositions for treating diseases associated with pathogenic proteins |
US20100048713A1 (en) * | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
RU2008135762A (ru) | 2006-02-16 | 2010-03-27 | Де МакЛин Хоспитал Корпорейшн (US) | Способы и композиции для лечения болезни паркинсона |
WO2010131717A1 (ja) * | 2009-05-14 | 2010-11-18 | 国立大学法人岐阜大学 | プリオンタンパク質構造変換抑制剤及びその利用 |
GB2568291A (en) * | 2017-11-13 | 2019-05-15 | Crisby Milita | New use |
CN108143734A (zh) * | 2018-02-09 | 2018-06-12 | 南京中医药大学 | 阿莫地喹及其药学上可接受的盐在制备用于治疗阿尔茨海默病的药物中的应用 |
EP3764102A4 (en) * | 2018-03-09 | 2021-12-15 | National University Corporation Tokyo Medical and Dental University | DETECTION OF ALZHEIMER'S DISEASE (MA), FRONTOTEMPORAL LOBAR DEGENERATION (FRONTOTEMPORAL LOBAR DEGENERATION), AMYOTROPHIC LATERAL SCLEROSIS (ALS), PARKINSON'S DISEASE (PD) AND INDICATED LEWY-BODY DEMENTIA (PARL) MARCKS PHOSPHORYLATION |
WO2023059867A1 (en) * | 2021-10-08 | 2023-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds for treating or preventing alzheimer's disease |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2546658A (en) * | 1949-07-23 | 1951-03-27 | Sterling Drug Inc | 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation |
BE759163A (fr) * | 1969-11-20 | 1971-05-19 | Merck & Co Inc | (p-sulfonilyl)phenyluree appliquee au traitement de la maladie de mare |
US3702362A (en) * | 1970-09-17 | 1972-11-07 | Merck & Co Inc | Use of ureido diphenyl sulfones in the treatment of marek's disease |
US3715375A (en) * | 1970-09-17 | 1973-02-06 | Merck & Co Inc | New diphenyl sulfones |
US3775403A (en) * | 1970-09-17 | 1973-11-27 | Merck & Co Inc | Diphenyl sulfones |
US3786050A (en) * | 1971-07-06 | 1974-01-15 | Merck & Co Inc | Diphenyl sulfones |
US3775444A (en) * | 1971-07-13 | 1973-11-27 | Merck & Co Inc | 4-amino,3-or 3'-fluoro-4'-ureido diphenyl sulfones |
US4338334A (en) * | 1977-12-29 | 1982-07-06 | Merck & Co., Inc. | 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases |
US4963565A (en) * | 1986-07-30 | 1990-10-16 | National Jewish Center For Immunology And Respiratory Medicine | In vivo treatment of mycobacterial infections with 6-cyclo octylamino-5,8-quinoline quinone |
US5532219A (en) * | 1991-04-23 | 1996-07-02 | The University Of British Columbia | Dapsone and promin for the treatment of dementia |
US6071493A (en) * | 1996-09-20 | 2000-06-06 | Baylor College Of Medicine | Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation |
US6043283A (en) | 1996-09-20 | 2000-03-28 | Baylor College Of Medicine | Tyramine compounds and their neuronal effects |
WO2001003649A2 (en) * | 1999-07-13 | 2001-01-18 | Alpha Research Group, Llc | Compositions and methods for the treatment of parkinson's disease |
US20020198231A1 (en) * | 1999-07-13 | 2002-12-26 | Jodi Nelson | Compositions and methods for the treatment of Parkinson's disease |
US20030092635A1 (en) * | 1999-12-08 | 2003-05-15 | Aberg A K Gunnar | Galenical preparations of dapsone and related sulphones, and method of therapeutic and preventative treatment of disease |
-
2004
- 2004-01-27 CA CA002514396A patent/CA2514396A1/en not_active Abandoned
- 2004-01-27 CA CA2514327A patent/CA2514327C/en not_active Expired - Fee Related
- 2004-01-27 ZA ZA200506000A patent/ZA200506000B/en unknown
- 2004-01-27 JP JP2006503038A patent/JP2006516629A/ja active Pending
- 2004-01-27 JP JP2006503068A patent/JP4571619B2/ja not_active Expired - Fee Related
- 2004-01-27 CN CNB2004800084618A patent/CN100502847C/zh not_active Expired - Fee Related
- 2004-01-27 EP EP04705636A patent/EP1594485A4/en not_active Withdrawn
- 2004-01-27 AU AU2004207561A patent/AU2004207561B2/en not_active Ceased
- 2004-01-27 WO PCT/US2004/002236 patent/WO2004066943A2/en active Application Filing
- 2004-01-27 US US10/495,553 patent/US20060035929A1/en not_active Abandoned
- 2004-01-27 EP EP04705647A patent/EP1592388B1/en not_active Expired - Lifetime
- 2004-01-27 DE DE602004026683T patent/DE602004026683D1/de not_active Expired - Lifetime
- 2004-01-27 CN CNA2004800083935A patent/CN101238370A/zh active Pending
- 2004-01-27 ZA ZA200506033A patent/ZA200506033B/xx unknown
- 2004-01-27 KR KR1020057013879A patent/KR20050119104A/ko not_active Application Discontinuation
- 2004-01-27 AT AT04705647T patent/ATE465408T1/de not_active IP Right Cessation
- 2004-01-27 KR KR1020057013878A patent/KR20060002752A/ko not_active Application Discontinuation
- 2004-01-27 WO PCT/US2004/002147 patent/WO2004066940A2/en active Application Filing
- 2004-01-27 AU AU2004207551A patent/AU2004207551B2/en not_active Ceased
-
2005
- 2005-07-26 IL IL169889A patent/IL169889A/en not_active IP Right Cessation
-
2007
- 2007-02-05 US US11/671,372 patent/US20070129439A1/en not_active Abandoned
-
2009
- 2009-03-10 AU AU2009200927A patent/AU2009200927A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004066940A3 (en) | 2005-01-20 |
AU2004207561B2 (en) | 2009-07-30 |
CN101238370A (zh) | 2008-08-06 |
EP1592388A4 (en) | 2008-08-06 |
AU2009200927A1 (en) | 2009-04-02 |
US20060035929A1 (en) | 2006-02-16 |
IL169889A (en) | 2011-04-28 |
CA2514396A1 (en) | 2004-08-12 |
CA2514327A1 (en) | 2004-08-12 |
JP2006516629A (ja) | 2006-07-06 |
CN1819822A (zh) | 2006-08-16 |
WO2004066943A3 (en) | 2008-03-27 |
AU2004207561A1 (en) | 2004-08-12 |
CN100502847C (zh) | 2009-06-24 |
JP2007524353A (ja) | 2007-08-30 |
ZA200506000B (en) | 2007-11-28 |
DE602004026683D1 (de) | 2010-06-02 |
AU2004207551B2 (en) | 2008-12-11 |
EP1594485A2 (en) | 2005-11-16 |
IL169889A0 (en) | 2007-07-04 |
EP1594485A4 (en) | 2009-01-14 |
WO2004066940A2 (en) | 2004-08-12 |
AU2004207551A1 (en) | 2004-08-12 |
JP4571619B2 (ja) | 2010-10-27 |
KR20050119104A (ko) | 2005-12-20 |
US20070129439A1 (en) | 2007-06-07 |
WO2004066943A2 (en) | 2004-08-12 |
EP1592388A2 (en) | 2005-11-09 |
KR20060002752A (ko) | 2006-01-09 |
EP1592388B1 (en) | 2010-04-21 |
CA2514327C (en) | 2013-04-02 |
ATE465408T1 (de) | 2010-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1087398A1 (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
IL169889A0 (en) | Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin | |
IL157946A0 (en) | Combination therapy | |
TR200002773T2 (tr) | Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı. | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
GB0117326D0 (en) | Napthoquinone-type inhibitors of protein aggregation | |
WO2006001877A3 (en) | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen | |
MX2008009947A (es) | Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos. | |
GB0108592D0 (en) | Therapeutic agents | |
SG149063A1 (en) | Use of modified cyclosporins for the treatment of hcv disorders | |
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
SG157231A1 (en) | Substituted p-diaminobenzene derivatives | |
IL146125A0 (en) | Novel quinones as disease therapies | |
IL171384A (en) | Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders | |
MXPA04003298A (es) | Compuestos de piperidina como antagonistas muscarinicos. | |
MY135829A (en) | Analeptic and drug combinations | |
AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
DK1220852T3 (da) | Substituerede diazepaner | |
MY139368A (en) | Novel cyclohexyl sulphones | |
WO2004099388A3 (en) | Cbl-b polypeptides, complexes and related methods | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
DK1196442T3 (da) | VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser | |
ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
WO2004101766A3 (en) | Grp94-based compositions and methods of use thereof | |
DE60222552D1 (de) | Carbamate von 2-heterozyklischen 1,2-ethandiolen |